![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
MH Hsu, CN Palmer, KJ Griffin and EF Johnson
Department of Molecular and Experimental Medicine, Scripps Research Institute, La Jolla, California 92037, USA.
The mouse peroxisome proliferator-activated receptor alpha (mP-PAR alpha) can activate transcription from the CYP4A6 promoter in transient cotransfection experiments in the absence (intrinsic transactivation) or presence of added peroxisome proliferator. However, mPPAR alpha-G, in which glycine is substituted for Glu282, exhibits very low intrinsic transactivation and responds fully to added peroxisome proliferators. The two receptors, when expressed in COS-1 cells, are nuclear in localization, are expressed at similar levels, have similar stability, and bind DNA in vitro with similar efficiency. The phenotypic difference in intrinsic transactivation is not altered by overexpression of the human retinoid X receptor alpha. The mPPAR alpha- G mutant receptor displays a higher EC50 for pirinixic acid and for 5,8,11,14-eicosatetraynoic acid than the wild-type PPAR alpha. This difference in the apparent EC50 value is independent of the cell lines used and indicates that the Glu282 to glycine substitution alters the response of mPPAR alpha to peroxisome proliferators. The EC50 values obtained for each receptor with the CYP4A6 reporter construct are lower than those for a reporter derived from the acyl-CoA oxidase gene. In general, an inverse relation is evident between the apparent EC50 values and the extent of intrinsic transactivation observed. The difference in intrinsic transactivation may reflect the presence of an endogenous activator at a concentration that is not sufficient to activate the mPPAR alpha-G but that is sufficient to effect the intrinsic transactivation seen for the wild-type mPPAR alpha.
This article has been cited by other articles:
|
|
 |
|
  J. M. Shipley, C. H. Hurst, S. S. Tanaka, F. L. DeRoos, J. L. Butenhoff, A. M. Seacat, and D. J. Waxman trans-Activation of PPAR{alpha} and Induction of PPAR{alpha} Target Genes by Perfluorooctane-Based Chemicals Toxicol. Sci., July 1, 2004; 80(1): 151 - 160. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Cowart, S. Wei, M.-H. Hsu, E. F. Johnson, M. U. Krishna, J. R. Falck, and J. H. Capdevila The CYP4A Isoforms Hydroxylate Epoxyeicosatrienoic Acids to Form High Affinity Peroxisome Proliferator-activated Receptor Ligands J. Biol. Chem., September 13, 2002; 277(38): 35105 - 35112. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. E. Akiyama, C. T. Baumann, S. Sakai, G. L. Hager, and F. J. Gonzalez Selective Intranuclear Redistribution of PPAR Isoforms by RXR{alpha} Mol. Endocrinol., April 1, 2002; 16(4): 707 - 721. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Rodríguez, V. Noé, A. Cabrero, C. J. Ciudad, and J. C. Laguna Differences in the Formation of PPARalpha -RXR/acoPPRE Complexes between Responsive and Nonresponsive Species upon Fibrate Administration Mol. Pharmacol., July 1, 2000; 58(1): 185 - 193. [Abstract] [Full Text]
|
|
|
|
 |
|
 B. Desvergne and W. Wahli Peroxisome Proliferator-Activated Receptors: Nuclear Control of Metabolism Endocr. Rev., October 1, 1999; 20(5): 649 - 688. [Abstract] [Full Text]
|
|
|
|
|
|
P. Costet, C. Legendre, J. More, A. Edgar, P. Galtier, and T. Pineau Peroxisome Proliferator-activated Receptor alpha -Isoform Deficiency Leads to Progressive Dyslipidemia with Sexually Dimorphic Obesity and Steatosis J. Biol. Chem., November 6, 1998; 273(45): 29577 - 29585. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-H. Hsu, C. N. A. Palmer, W. Song, K. J. Griffin, and E. F. Johnson A Carboxyl-terminal Extension of the Zinc Finger Domain Contributes to the Specificity and Polarity of Peroxisome Proliferator-activated Receptor DNA Binding J. Biol. Chem., October 23, 1998; 273(43): 27988 - 27997. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. N. A. Palmer, M.-H. Hsu, K. J. Griffin, J. L. Raucy, and E. F. Johnson Peroxisome Proliferator Activated Receptor-alpha Expression in Human Liver Mol. Pharmacol., January 1, 1998; 53(1): 14 - 22. [Abstract] [Full Text]
|
|
|
|
|
|
P. Dowell, J. E. Ishmael, D. Avram, V. J. Peterson, D. J. Nevrivy, and M. Leid p300 Functions as a Coactivator for the Peroxisome Proliferator-activated Receptor alpha J. Biol. Chem., December 26, 1997; 272(52): 33435 - 33443. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Fraser, D. Keller, V. Martinez, D. Santiso-Mere, R. Straney, and M. R. Briggs Utilization of Recombinant Adenovirus and Dominant Negative Mutants to Characterize Hepatocyte Nuclear Factor 4-regulated Apolipoprotein AI and CIII Expression J. Biol. Chem., May 23, 1997; 272(21): 13892 - 13898. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. M. Forman, J. Chen, and R. M. Evans Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta PNAS, April 29, 1997; 94(9): 4312 - 4317. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Dowell, V. J. Peterson, T. M. Zabriskie, and M. Leid Ligand-induced Peroxisome Proliferator-activated Receptor alpha Conformational Change J. Biol. Chem., January 17, 1997; 272(3): 2013 - 2020. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-H. Hsu, U. Savas, K. J. Griffin, and E. F. Johnson Identification of Peroxisome Proliferator-responsive Human Genes by Elevated Expression of the Peroxisome Proliferator-activated Receptor alpha in HepG2 Cells J. Biol. Chem., July 20, 2001; 276(30): 27950 - 27958. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
